AR122185A2 - Comprimido farmacéutico que comprende el solvato de dimetilsulfóxido de la n-3-[3-ciclopropil-5-(2-fluoro-4-yodo-fenilamino)-6,8-dimetil-2,4,7-trioxo-3,4,6,7-tetrahidro-2h-pirido[4,3-d]pirimidin-1-il]fenilacetamida, su uso para preparar un medicamento útil para tratar el cáncer en un ser humano y procedimiento para preparar dichos comprimidos - Google Patents

Comprimido farmacéutico que comprende el solvato de dimetilsulfóxido de la n-3-[3-ciclopropil-5-(2-fluoro-4-yodo-fenilamino)-6,8-dimetil-2,4,7-trioxo-3,4,6,7-tetrahidro-2h-pirido[4,3-d]pirimidin-1-il]fenilacetamida, su uso para preparar un medicamento útil para tratar el cáncer en un ser humano y procedimiento para preparar dichos comprimidos

Info

Publication number
AR122185A2
AR122185A2 ARP210101433A ARP210101433A AR122185A2 AR 122185 A2 AR122185 A2 AR 122185A2 AR P210101433 A ARP210101433 A AR P210101433A AR P210101433 A ARP210101433 A AR P210101433A AR 122185 A2 AR122185 A2 AR 122185A2
Authority
AR
Argentina
Prior art keywords
preparing
dimethyl
trioxo
pyrido
phenylamino
Prior art date
Application number
ARP210101433A
Other languages
English (en)
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46314827&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR122185(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of AR122185A2 publication Critical patent/AR122185A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J3/00—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms
    • A61J3/06—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms into the form of pills, lozenges or dragees
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J3/00—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms
    • A61J3/10—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms into the form of compressed tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2813—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Comprimido farmacéutico que comprende: a) una cantidad de fármaco, que es el solvato de dimetilsulfóxido de la N-{3-[3-ciclopropil-5-(2-fluoro-4-yodo-fenilamino)-6,8-dimetil-2,4,7-trioxo-3,4,6,7-tetrahidro-2H-pirido[4,3-d]pirimidin-1-il]fenil}acetamida, seleccionada entre 0,5635 mg y 2,254 mg; en el que el comprimido contiene de 25% a 89% en peso de uno o más excipientes, en el que los excipientes carecen sustancialmente de agua y la cantidad de fármaco no solvatado no supera 20%. Los excipientes se seleccionan entre: celulosa microcristalina, celulosa en polvo, almidón pregelatinizado, almidón, lactosa, fosfato dicálcico, lactitol, manitol, sorbitol y maltodextrina. Su uso para preparar un medicamento útil para tratar el cáncer en un ser humano. Procedimiento para preparar dichos comprimidos. Reivindicación 1: Un comprimido farmacéutico caracterizado porque comprende un fármaco que es solvato de dimetilsulfóxido de la N-{3-[3-ciclopropil-5-(2-fluoro-4-yodo-fenilamino)-6,8-dimetil-2,4,7-trioxo-3,4,6,7-tetrahidro-2H-pirido[4,3-d]pirimidin-1-il]fenil}acetamida (Compuesto A) en forma micronizada y un desintegrante o desintegrantes, en el que al menos el 50% o el las partículas del fármaco son de 30 micrones o menos.
ARP210101433A 2010-12-20 2021-05-27 Comprimido farmacéutico que comprende el solvato de dimetilsulfóxido de la n-3-[3-ciclopropil-5-(2-fluoro-4-yodo-fenilamino)-6,8-dimetil-2,4,7-trioxo-3,4,6,7-tetrahidro-2h-pirido[4,3-d]pirimidin-1-il]fenilacetamida, su uso para preparar un medicamento útil para tratar el cáncer en un ser humano y procedimiento para preparar dichos comprimidos AR122185A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201061424967P 2010-12-20 2010-12-20

Publications (1)

Publication Number Publication Date
AR122185A2 true AR122185A2 (es) 2022-08-24

Family

ID=46314827

Family Applications (2)

Application Number Title Priority Date Filing Date
ARP110104773A AR084102A1 (es) 2010-12-20 2011-12-19 Comprimido farmaceutico que comprende el solvato de dimetilsulfoxido de la n-{3-[3-ciclopropil-5-(2-fluoro-4-yodo-fenilamino)-6,8-dimetil-2,4,7-trioxo-3,4,6,7-tetrahidro-2h-pirido[4,3-d]pirimidin-1-il]fenil}acetamida, su uso para preparar un medicamento util para tratar el cancer en un ser humano y procedimiento para preparar dichos comprimidos
ARP210101433A AR122185A2 (es) 2010-12-20 2021-05-27 Comprimido farmacéutico que comprende el solvato de dimetilsulfóxido de la n-3-[3-ciclopropil-5-(2-fluoro-4-yodo-fenilamino)-6,8-dimetil-2,4,7-trioxo-3,4,6,7-tetrahidro-2h-pirido[4,3-d]pirimidin-1-il]fenilacetamida, su uso para preparar un medicamento útil para tratar el cáncer en un ser humano y procedimiento para preparar dichos comprimidos

Family Applications Before (1)

Application Number Title Priority Date Filing Date
ARP110104773A AR084102A1 (es) 2010-12-20 2011-12-19 Comprimido farmaceutico que comprende el solvato de dimetilsulfoxido de la n-{3-[3-ciclopropil-5-(2-fluoro-4-yodo-fenilamino)-6,8-dimetil-2,4,7-trioxo-3,4,6,7-tetrahidro-2h-pirido[4,3-d]pirimidin-1-il]fenil}acetamida, su uso para preparar un medicamento util para tratar el cancer en un ser humano y procedimiento para preparar dichos comprimidos

Country Status (37)

Country Link
US (5) US20130266649A1 (es)
EP (4) EP2654736B1 (es)
JP (2) JP6126014B2 (es)
KR (1) KR101911109B1 (es)
CN (1) CN103998041B (es)
AR (2) AR084102A1 (es)
AU (1) AU2011349422B2 (es)
BR (1) BR112013015602B1 (es)
CA (1) CA2822701C (es)
CL (1) CL2013001779A1 (es)
CR (1) CR20130352A (es)
CY (1) CY1123376T1 (es)
DK (3) DK4159205T3 (es)
DO (1) DOP2013000138A (es)
EA (1) EA025198B1 (es)
ES (1) ES2820536T3 (es)
FI (2) FI4159205T3 (es)
HR (1) HRP20201409T1 (es)
HU (1) HUE050788T2 (es)
IL (1) IL226855A (es)
JO (1) JO3594B1 (es)
LT (3) LT2654736T (es)
MA (1) MA34883B1 (es)
MX (1) MX2013007073A (es)
MY (1) MY170501A (es)
NZ (1) NZ612157A (es)
PE (1) PE20140040A1 (es)
PL (2) PL2654736T3 (es)
PT (3) PT4159204T (es)
RS (2) RS65496B1 (es)
SG (1) SG191054A1 (es)
SI (3) SI4159204T1 (es)
TW (1) TWI505828B (es)
UA (1) UA113158C2 (es)
UY (1) UY33818A (es)
WO (1) WO2012088033A2 (es)
ZA (1) ZA201304189B (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2879252C (en) 2012-08-17 2017-10-10 F. Hoffmann-La Roche Ag Combination therapies for melanoma comprising administering cobimetinib and vemurafinib
ES2686730T3 (es) * 2012-11-30 2018-10-19 Novartis Ag Composición farmacéutica novedosa
WO2015019125A1 (en) * 2013-08-05 2015-02-12 Societe De Developpement Et De Recherche Industrielle Molecular targets for the treatment of wounds, in particular chronic wounds
CN103819471A (zh) * 2013-11-25 2014-05-28 镇江圣安医药有限公司 吡啶并(4,3-d)嘧啶-1（2H）-基苯基乙酰胺的衍生物及其应用
WO2015081566A1 (zh) * 2013-12-06 2015-06-11 杭州普晒医药科技有限公司 曲美替尼及其溶剂化物的晶型、其制备方法、含有它们的药物组合物及其用途
EP2913048A1 (en) * 2014-02-27 2015-09-02 ratiopharm GmbH Pharmaceutical composition comprising trametinib
KR101545268B1 (ko) 2015-02-05 2015-08-20 보령제약 주식회사 정제 및 이의 제조방법
WO2016126012A1 (en) * 2015-02-05 2016-08-11 Boryung Pharmaceutical Co., Ltd Tablet and method of preparing the same
US20170020880A1 (en) * 2015-07-22 2017-01-26 Hetero Research Foundation Pharmaceutical compositions of trametinib
JP6875501B2 (ja) 2016-08-10 2021-05-26 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト Ａｋｔプロテインキナーゼ阻害剤を含む薬学的組成物
RU2627692C1 (ru) 2016-10-10 2017-08-10 Закрытое акционерное общество "Р-Фарм" (ЗАО "Р-Фарм") N-{ 3-[3-циклопропил-5-(2-фторо-4-иодофениламино)-6,8-диметил-2,4,7-триоксо-3,4,6,7-тетрагидро-2Н-пиридо[4,3-d]пиримидин-1-ил]-фенил} -циклопропанкарбоксамида диметилсульфоксида сольват в качестве ингибитора МЕК1/2
JP2019535696A (ja) 2016-11-25 2019-12-12 ジエンス ヘンルイ メデイシンカンパニー リミテッドＪｉａｎｇｓｕ Ｈｅｎｇｒｕｉ Ｍｅｄｉｃｉｎｅ Ｃｏ．，Ｌｔｄ． ピリドン誘導体の医薬組成物およびその製造方法
KR102641827B1 (ko) 2017-05-02 2024-03-04 노파르티스 아게 병용 요법
RU2749719C1 (ru) * 2020-10-08 2021-06-16 Нестерук Владимир Викторович Препарат для лечения анемии, связанной с хроническим заболеванием почек, и способ его получения
WO2023105286A1 (en) 2021-12-06 2023-06-15 My Personal Therapeutics Ltd A combination treatment for cancer

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4727077A (en) 1985-02-20 1988-02-23 Ishihara Sangyo Kaisha Ltd. Benzoyl urea compounds, process for their production, and antitumorous compositions containing them
JPS61205257A (ja) * 1985-03-08 1986-09-11 Ishihara Sangyo Kaisha Ltd ベンゾイルウレア系化合物、その製法及びそれを含有する抗ガン剤
US5559235A (en) 1991-10-29 1996-09-24 Glaxo Wellcome Inc. Water soluble camptothecin derivatives
US5342947A (en) 1992-10-09 1994-08-30 Glaxo Inc. Preparation of water soluble camptothecin derivatives
US5681835A (en) 1994-04-25 1997-10-28 Glaxo Wellcome Inc. Non-steroidal ligands for the estrogen receptor
US5491237A (en) 1994-05-03 1996-02-13 Glaxo Wellcome Inc. Intermediates in pharmaceutical camptothecin preparation
GB9716557D0 (en) 1997-08-06 1997-10-08 Glaxo Group Ltd Benzylidene-1,3-dihydro-indol-2-one derivatives having anti-cancer activity
US6825180B2 (en) 2001-05-18 2004-11-30 Cell Therapeutics, Inc. Pyridopyrimidine compounds and their uses
US7378423B2 (en) * 2004-06-11 2008-05-27 Japan Tobacco Inc. Pyrimidine compound and medical use thereof
PL2298768T3 (pl) * 2004-06-11 2013-03-29 Japan Tobacco Inc Pochodne 5-amino-2,4,7-triokso-3,4,7,8-tetrahydro-2H-pirydo[2,3-d]pirymidyny i związki pokrewne do leczenia nowotworu
WO2008048469A2 (en) * 2006-10-13 2008-04-24 Actavis Group Pct Hf Controlled-release coated dosage forms containing galantamine
WO2008060890A2 (en) * 2006-11-09 2008-05-22 Gilead Colorado, Inc. Darusentan oral dosage form
JO2985B1 (ar) * 2006-12-20 2016-09-05 Takeda Pharmaceuticals Co مثبطات كينازmapk/erk
UY30892A1 (es) 2007-02-07 2008-09-02 Smithkline Beckman Corp Inhibidores de la actividad akt
ECSP077628A (es) 2007-05-03 2008-12-30 Smithkline Beechman Corp Nueva composición farmacéutica
JP5479337B2 (ja) * 2007-07-30 2014-04-23 アルディア バイオサイエンス，インク． Ｍｅｋ阻害剤およびｒａｆキナーゼ阻害剤の組み合わせ、ならびにその使用
BRPI0817946A2 (pt) * 2007-09-25 2015-05-05 Teva Pharma Composições de imatinibe estável
AU2009267683B2 (en) * 2008-07-08 2014-04-03 Beta Pharma, Inc. Icotinib hydrochloride, synthesis, crystallographic form, medical combination, and uses thereof
MX2012003546A (es) 2009-09-23 2012-09-07 Glaxosmithkline Llc Combinacion.
ES2527831T3 (es) 2009-09-23 2015-01-30 Glaxosmithkline Llc Combinación que comprende el inhibidor de MEK: N-{3-[3-ciclopropil-5-(2-fluoro-4-yodo-fenilamino)-6,8-dimetil-2,4,7-trioxo-3,4,6,7-tetrahidro-2H-pirido[4,3-d]pirimidin-1-il]fenil}acetamida y el inhibidor de Akt: N-{(1S)-2-amino-1-[(3-fluorofenil)metil]etil}-5-cloro-4-(4-cloro-1-metil-1H-pirazol-5-il)-2-tiofenocarboxamida
CA2775874A1 (en) 2009-09-28 2011-03-31 Glaxosmithkline Llc Combination
LT3560498T (lt) 2009-10-16 2022-11-25 Novartis Ag Derinys apimantis mek inhibitorių ir b-raf inhibitorių
AU2010322105B2 (en) 2009-11-17 2014-05-08 Novartis Ag Combination
US20130165456A1 (en) 2010-08-26 2013-06-27 Tona M. Gilmer Combination
US8977217B1 (en) 2013-02-20 2015-03-10 Triquint Semiconductor, Inc. Switching device with negative bias circuit

Also Published As

Publication number Publication date
EP2654736A2 (en) 2013-10-30
WO2012088033A3 (en) 2014-03-13
FI4159205T3 (fi) 2024-04-23
UA113158C2 (xx) 2016-12-26
AU2011349422B2 (en) 2015-12-10
US9399021B2 (en) 2016-07-26
CA2822701A1 (en) 2012-06-28
RS65496B1 (sr) 2024-06-28
US20140099365A1 (en) 2014-04-10
KR101911109B1 (ko) 2018-10-23
AU2011349422A1 (en) 2013-05-02
SI4159204T1 (sl) 2024-06-28
ES2820536T3 (es) 2021-04-21
JP2014510704A (ja) 2014-05-01
CN103998041B (zh) 2016-08-17
CR20130352A (es) 2013-12-18
DK4159204T3 (da) 2024-05-21
EP2654736B1 (en) 2020-07-01
US9271941B2 (en) 2016-03-01
EA201390913A1 (ru) 2014-04-30
LT4159204T (lt) 2024-05-10
JP2017137299A (ja) 2017-08-10
SG191054A1 (en) 2013-08-30
EP4159204A1 (en) 2023-04-05
CA2822701C (en) 2018-10-23
KR20130130028A (ko) 2013-11-29
HRP20201409T1 (hr) 2020-11-27
JO3594B1 (ar) 2020-07-05
WO2012088033A2 (en) 2012-06-28
SI4159205T1 (sl) 2024-06-28
EP4159205A1 (en) 2023-04-05
MA34883B1 (fr) 2014-02-01
CN103998041A (zh) 2014-08-20
CL2013001779A1 (es) 2014-06-27
SI2654736T1 (sl) 2020-10-30
FI4159204T3 (fi) 2024-04-22
PT4159205T (pt) 2024-05-08
JP6126014B2 (ja) 2017-05-10
IL226855A (en) 2017-04-30
ZA201304189B (en) 2014-02-26
US9155706B2 (en) 2015-10-13
LT2654736T (lt) 2020-09-25
PT2654736T (pt) 2020-09-24
US20140154316A1 (en) 2014-06-05
MY170501A (en) 2019-08-08
PT4159204T (pt) 2024-05-07
UY33818A (es) 2012-07-31
PL2654736T3 (pl) 2020-12-14
EA025198B1 (ru) 2016-11-30
CY1123376T1 (el) 2021-12-31
LT4159205T (lt) 2024-05-10
EP4159205B1 (en) 2024-02-14
TW201249441A (en) 2012-12-16
US20120183613A1 (en) 2012-07-19
US20140037726A1 (en) 2014-02-06
DK4159205T3 (da) 2024-05-13
TWI505828B (zh) 2015-11-01
RS65497B1 (sr) 2024-06-28
PE20140040A1 (es) 2014-02-26
NZ612157A (en) 2015-05-29
DOP2013000138A (es) 2013-11-30
EP3808343A1 (en) 2021-04-21
US8580304B2 (en) 2013-11-12
BR112013015602B1 (pt) 2022-03-03
EP4159204B1 (en) 2024-02-14
DK2654736T3 (da) 2020-09-14
US20130266649A1 (en) 2013-10-10
MX2013007073A (es) 2013-09-26
HUE050788T2 (hu) 2021-01-28
AR084102A1 (es) 2013-04-24
PL4159205T3 (pl) 2024-06-24
EP2654736A4 (en) 2015-04-22
BR112013015602A2 (pt) 2017-02-21

Similar Documents

Publication Publication Date Title
AR122185A2 (es) Comprimido farmacéutico que comprende el solvato de dimetilsulfóxido de la n-3-[3-ciclopropil-5-(2-fluoro-4-yodo-fenilamino)-6,8-dimetil-2,4,7-trioxo-3,4,6,7-tetrahidro-2h-pirido[4,3-d]pirimidin-1-il]fenilacetamida, su uso para preparar un medicamento útil para tratar el cáncer en un ser humano y procedimiento para preparar dichos comprimidos
AR118108A2 (es) Formas cristalinas de un inhibidor de tirosina quinasa de bruton
ES2574836T3 (es) Formulación de liberación prolongada de nevirapina
BRPI0606332A2 (pt) composição farmacêutica de bendamustina, preparação liofilizada, forma de dosagem farmacêutica, método para obter aprovação oficial para um produto de bendamustina, processo para fabricar uma preparação liofilizada de bendamustina, solução ou dispersão de pré-liofilização de bendamustina, pó liofilizado, método para preparar uma preparação liofilizada de bendamustina, formulação para liofilização, e, uso de uma solução farmaceuticamente aceitável
HRP20201162T1 (hr) Farmaceutski sastav koji može uključiti lenalidomid u različitim kristaliničnim modifikacijama
UA116334C2 (uk) Тверді форми дозування бендамустину
AR107391A1 (es) Formulaciones / composiciones que comprenden un inhibidor de btk
AR096892A1 (es) Una combinación farmacéutica para el tratamiento del melanoma
RU2013154355A (ru) Способ лечения мезотелиомы ингибитором рi3к
EA201590797A1 (ru) Препараты с модифицированным высвобождением опрозомиба
AR077284A1 (es) Composiciones de dosis fija farmaceuticas solidas que comprenden irbesartan y amlodipina, su preparacion y su aplicacion terapeutica
AR100977A1 (es) Formulación compuesta para la administración oral que comprende ezetimiba y rosuvastatina, y un proceso para su preparación
UY30636A1 (es) Composision farmaceutica de liberacon modificada de un musculo relajante y un aine
BR112012030654A2 (pt) formas de dosagem oral de bendamustina
AR097512A1 (es) Forma de dosis unitaria que comprende emtricitabina, tenofovir, darunavir y ritonavir y un comprimido monolítico que comprende darunavir y ritonavir
BR112015020443A2 (pt) desamorfização de formulações secadas por atomização via mistura por atomização
AR080895A1 (es) Formulacion de comprimido de ezatiostat
EA201170583A1 (ru) Новая композиция для лечения эссенциальной тромбоцитемии
BR112016015175A2 (pt) Formulação farmacêutica, método para a fabricação de uma formulação farmacêutica compreendendo sildenafila e clomipramina e comprimido
PH12018500889A1 (en) Pharmaceutical preparation for delivery of porous material to large intestine or lower part of small intestine
PH12016502540A1 (en) Pharmaceutical dosage forms
CO2018010142A2 (es) Proceso de preparación de fórmulas solidas de mesalazina
GT200600242A (es) Formulaciones farmaceuticas de liberacion inmediata y con una carga de droga elevada de (4-clorofenil)[4-(4-piridilmetil)ftalazin-1-ilo] no micronizado, y sus sales
UY37413A (es) Formulaciones de liberación inmediata de oprozomib
WO2013054178A8 (en) Extended release pharmaceutical compositions containing carmabazepine